You are here: Home » Current Affairs » News » Health
Business Standard

HC quashes ban on 344 fixed dose combination medicines

The government had banned over 300 FDC drugs on the ground that they involve "risk" to humans

Press Trust of India  |  New Delhi 

Delhi High Court (Photo - PTI)
Delhi High Court. Photo: PTI

In a blow to the Centre, its decision to ban 344 (FDC) medicines, including well known brands like Corex cough syrup, extra and several anti-diabetes medication, was on Thursday set aside by the Delhi which said the step was taken in a "haphazard manner".

J. Rajiv Sahai Endlaw allowed 454 petitions moved by various pharma and healthcare majors, like Pfizer, Glenmark, Procter and Gamble and Cipla, challenging the government's March 10 notification banning the FDCs, saying the decision was taken by the Centre without following procedure prescribed in the Drugs and Cosmetics Act.



The court had from March 14 onwards stayed the operation of the Centre's decision with regard to of several pharma majors.

The court on Thursday said that proceedings till issuance of the notification of March 10, 2016, "do not suggest there was any grave urgency".

It also said that the power under section 26A (power to prohibit manufacture of drugs and cosmetics in public interest) of Drugs and Cosmetics Act cannot be exercised in public interest except when a drug poses a risk to consumers.

During the hearing in the case, the drug companies had contended that the government has not properly implemented the powers under section 26A, under which the ban was ordered.

They had also argued that the ban order was passed without considering clinical data and had termed as "absurd" the government's claim that it took the decision to ban FDCs on the ground that safer alternatives were available.

The government had banned over 300 drugs on the ground that they involve "risk" to humans and safer alternatives were available.

As per the March 10 notification, "On the basis of recommendations of an expert committee, the central government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of said drugs in the country.

RECOMMENDED FOR YOU

HC quashes ban on 344 fixed dose combination medicines

The government had banned over 300 FDC drugs on the ground that they involve "risk" to humans

The government had banned over 300 FDC drugs on the ground that they involve "risk" to humans In a blow to the Centre, its decision to ban 344 (FDC) medicines, including well known brands like Corex cough syrup, extra and several anti-diabetes medication, was on Thursday set aside by the Delhi which said the step was taken in a "haphazard manner".

J. Rajiv Sahai Endlaw allowed 454 petitions moved by various pharma and healthcare majors, like Pfizer, Glenmark, Procter and Gamble and Cipla, challenging the government's March 10 notification banning the FDCs, saying the decision was taken by the Centre without following procedure prescribed in the Drugs and Cosmetics Act.

The court had from March 14 onwards stayed the operation of the Centre's decision with regard to of several pharma majors.

The court on Thursday said that proceedings till issuance of the notification of March 10, 2016, "do not suggest there was any grave urgency".

It also said that the power under section 26A (power to prohibit manufacture of drugs and cosmetics in public interest) of Drugs and Cosmetics Act cannot be exercised in public interest except when a drug poses a risk to consumers.

During the hearing in the case, the drug companies had contended that the government has not properly implemented the powers under section 26A, under which the ban was ordered.

They had also argued that the ban order was passed without considering clinical data and had termed as "absurd" the government's claim that it took the decision to ban FDCs on the ground that safer alternatives were available.

The government had banned over 300 drugs on the ground that they involve "risk" to humans and safer alternatives were available.

As per the March 10 notification, "On the basis of recommendations of an expert committee, the central government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of said drugs in the country.
image
Business Standard
177 22

HC quashes ban on 344 fixed dose combination medicines

The government had banned over 300 FDC drugs on the ground that they involve "risk" to humans

In a blow to the Centre, its decision to ban 344 (FDC) medicines, including well known brands like Corex cough syrup, extra and several anti-diabetes medication, was on Thursday set aside by the Delhi which said the step was taken in a "haphazard manner".

J. Rajiv Sahai Endlaw allowed 454 petitions moved by various pharma and healthcare majors, like Pfizer, Glenmark, Procter and Gamble and Cipla, challenging the government's March 10 notification banning the FDCs, saying the decision was taken by the Centre without following procedure prescribed in the Drugs and Cosmetics Act.

The court had from March 14 onwards stayed the operation of the Centre's decision with regard to of several pharma majors.

The court on Thursday said that proceedings till issuance of the notification of March 10, 2016, "do not suggest there was any grave urgency".

It also said that the power under section 26A (power to prohibit manufacture of drugs and cosmetics in public interest) of Drugs and Cosmetics Act cannot be exercised in public interest except when a drug poses a risk to consumers.

During the hearing in the case, the drug companies had contended that the government has not properly implemented the powers under section 26A, under which the ban was ordered.

They had also argued that the ban order was passed without considering clinical data and had termed as "absurd" the government's claim that it took the decision to ban FDCs on the ground that safer alternatives were available.

The government had banned over 300 drugs on the ground that they involve "risk" to humans and safer alternatives were available.

As per the March 10 notification, "On the basis of recommendations of an expert committee, the central government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of said drugs in the country.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard